UBS Group’s Putnam BioRevolution ETF SYNB Stock Holding History

UBS Group’s Portfolio SYNB Stock Details SYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,013	Closed	-$30.3K	–	11137
2025 Q3	$30.3K	Buy	1,013 +1,000	+7,692%	+$29.6K	﹤0.01%	7892
2025 Q2	$368	Hold	13	–	–	﹤0.01%	9847
2025 Q1	$364	Buy	13 +2	+18%	+$59	﹤0.01%	9807
2024 Q4	$325	Hold	11	–	–	﹤0.01%	9517
2024 Q3	$364	Sell	11 -1	-8%	-$32	﹤0.01%	8976
2024 Q2	$374	Hold	12	–	–	﹤0.01%	8949
2024 Q1	$372	Sell	12 -100	-89%	-$2.98K	﹤0.01%	8600
2023 Q4	$3.26K	Buy	+112	New	+$3K	﹤0.01%	7995
2023 Q1	–	Sell	-258	Closed	-$6.7K	–	10346
2022 Q4	$6.7K	Buy	+258	New	+$6.69K	﹤0.01%	8997

UBS Group's SYNB Position: Q4 2025 in Review

UBS Group sold out of Putnam BioRevolution ETF (SYNB) in Q4 2025, closing a stake of 1,013 shares — an estimated $30.3K sold.

UBS Group first reported a position in SYNB in Q4 2022 and held it in 9 quarters. The position peaked at $30.3K in Q3 2025. 0 funds tracked by Wall St. Rank hold SYNB as of Q4 2025.

UBS Group reported no remaining Putnam BioRevolution ETF position as of Q4 2025 after selling out during the quarter.
UBS Group sold 1,013 Putnam BioRevolution ETF shares in Q4 2025, an estimated $30.3K.
UBS Group first reported a position in Putnam BioRevolution ETF in Q4 2022 and held it in 9 quarters.
UBS Group's Putnam BioRevolution ETF position peaked at $30.3K in Q3 2025.
0 funds tracked by Wall St. Rank held Putnam BioRevolution ETF as of Q4 2025.

Based on UBS Group's 13F filing for Q4 2025, filed 29 Jan 2026.